- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 493/08 - Bridged systems
Patent holdings for IPC class C07D 493/08
Total number of patents in this class: 911
10-year publication summary
|
53
|
61
|
79
|
70
|
49
|
49
|
61
|
50
|
60
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| VALO Health, Inc. | 182 |
37 |
| Novartis AG | 10463 |
21 |
| Lixte Biotechnology, Inc. | 62 |
20 |
| Pfizer Inc. | 3373 |
14 |
| Eisai R&D Management Co., Ltd. | 1193 |
14 |
| BASF Agro B.V. | 202 |
13 |
| President and Fellows of Harvard College | 6054 |
12 |
| Vanderbilt University | 1953 |
12 |
| Janssen Pharmaceutica N.V. | 3304 |
11 |
| Syngenta Limited | 438 |
10 |
| Gilead Sciences, Inc. | 2140 |
10 |
| Bristol-myers Squibb Company | 4795 |
9 |
| Abbvie Inc. | 1828 |
9 |
| Tokyo Ohka Kogyo Co., Ltd. | 1548 |
9 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2947 |
9 |
| F. Hoffmann-La Roche AG | 7878 |
8 |
| Purdue Research Foundation | 3795 |
8 |
| JNC Corporation | 1517 |
8 |
| JNC Petrochemical Corporation | 328 |
8 |
| Sunshine Lake Pharma Co., Ltd. | 613 |
8 |
| Other owners | 661 |